In recent years, the number of advanced non-small cell lung cancer (NSCLC) 
patients has gradually increased, and the treatment methods have also been 
significantly increased. However, there are no standard treatment plans at home 
and abroad for third-line and above patients who are refractory to targeted 
therapy epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) 
or chemotherapy. The clinical treatment effect is also not satisfactory. 
Anlotinib is a novel TKI targeting the vascular endothelial growth factor 
receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived 
growth factor receptor (PDGFR) and c-Kit. ALTER0303 trail, phase III study has 
demonstrated that Anlotinib significantly prolonged overall survival (OS) and 
progression-free survival (PFS) in advanced NSCLC patients as 3rd line 
treatment.Here we report a case of advanced lung adenocarcinoma harboring KRAS 
mutation treated with Anlotinib. .